Effect of oral ligustrazine phosphate with cerebroside carnosine on neurological function and serum inflammatory factors among patients with ischemic cerebrovascular disease: a quasi-experimental study.

IF 2.8 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

European Journal of Medical Research Pub Date : 2025-03-10 DOI:10.1186/s40001-025-02414-9

Qiong Zhao, Zhongyang Liu

{"title":"Effect of oral ligustrazine phosphate with cerebroside carnosine on neurological function and serum inflammatory factors among patients with ischemic cerebrovascular disease: a quasi-experimental study.","authors":"Qiong Zhao, Zhongyang Liu","doi":"10.1186/s40001-025-02414-9","DOIUrl":null,"url":null,"abstract":"Objectives: To explore the effect of ligustrazine phosphate tablets combined with cerebroside carnosine on neurological function and serum inflammatory factors among patients with ischemic cerebrovascular disease.Methods: This was a quasi-experimental study. From March 2019 to February 2022, 126 patients were non-randomly divided into control (n = 63) and intervention (n = 63) groups. The control group received routine treatment such as encephaloside and carnosine, while the intervention group was treated with ligustrazine phosphate tablets and brain glycoside carnosine for 2 weeks. Serum S-100β protein, nerve growth factor (NGF), inflammatory factors [tumor necrosis factor-α (TNF-α) and C-reactive protein (CRP)], National Institutes of Health Stroke scale (NIHSS) and and Activities of Daily Living (ADL) scale were assessed before and after the intervention.Results: After treatment, the level of S-100β in the intervention group was lower, and the level of NGF was significantly higher than in the control group. The levels of TNF-α and CRP in the intervention group were reduced. The NIHSS score of the intervention group was lower, and the ADL score was significantly higher than that of the control group.Conclusions: The combination of ligustrazine phosphate tablets with cerebroside carnosine can improve neurological function, alleviate inflammation, and enhance the quality of life, worthy of clinical promotion.","PeriodicalId":11949,"journal":{"name":"European Journal of Medical Research","volume":"30 1","pages":"158"},"PeriodicalIF":2.8000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11892308/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40001-025-02414-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: To explore the effect of ligustrazine phosphate tablets combined with cerebroside carnosine on neurological function and serum inflammatory factors among patients with ischemic cerebrovascular disease.

Methods: This was a quasi-experimental study. From March 2019 to February 2022, 126 patients were non-randomly divided into control (n = 63) and intervention (n = 63) groups. The control group received routine treatment such as encephaloside and carnosine, while the intervention group was treated with ligustrazine phosphate tablets and brain glycoside carnosine for 2 weeks. Serum S-100β protein, nerve growth factor (NGF), inflammatory factors [tumor necrosis factor-α (TNF-α) and C-reactive protein (CRP)], National Institutes of Health Stroke scale (NIHSS) and and Activities of Daily Living (ADL) scale were assessed before and after the intervention.

Results: After treatment, the level of S-100β in the intervention group was lower, and the level of NGF was significantly higher than in the control group. The levels of TNF-α and CRP in the intervention group were reduced. The NIHSS score of the intervention group was lower, and the ADL score was significantly higher than that of the control group.

Conclusions: The combination of ligustrazine phosphate tablets with cerebroside carnosine can improve neurological function, alleviate inflammation, and enhance the quality of life, worthy of clinical promotion.

查看原文本刊更多论文

口服磷酸川芎嗪联合脑苷肌肽对缺血性脑血管病患者神经功能及血清炎症因子影响的准实验研究

目的：探讨磷酸川芎嗪片联合脑苷肌肽对缺血性脑血管病患者神经功能及血清炎症因子的影响。方法：准实验研究。2019年3月至2022年2月，126例患者非随机分为对照组（n = 63）和干预组（n = 63）。对照组给予脑糖苷、肌肽等常规治疗，干预组给予磷酸川芎嗪片、脑糖苷肌肽治疗，疗程2周。评估干预前后血清S-100β蛋白、神经生长因子（NGF）、炎症因子[肿瘤坏死因子-α (TNF-α)和c反应蛋白（CRP）]、美国国立卫生研究院卒中量表（NIHSS）和日常生活活动（ADL）量表。结果：治疗后，干预组大鼠S-100β水平低于对照组，NGF水平明显高于对照组。干预组TNF-α、CRP水平降低。干预组NIHSS评分低于对照组，ADL评分显著高于对照组。结论：磷酸川芎嗪片联合脑苷肌肽可改善神经功能，减轻炎症，提高生活质量，值得临床推广。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Medical Research 医学-医学：研究与实验

CiteScore

3.20

自引率

0.00%

发文量

247

审稿时长

>12 weeks

期刊介绍： European Journal of Medical Research publishes translational and clinical research of international interest across all medical disciplines, enabling clinicians and other researchers to learn about developments and innovations within these disciplines and across the boundaries between disciplines. The journal publishes high quality research and reviews and aims to ensure that the results of all well-conducted research are published, regardless of their outcome.